Literature DB >> 31760362

Evaluation of the circadian rhythm of anti-Leishmania IgG2 and IgA antibodies in serum and saliva of dogs with clinical leishmaniosis.

Ana Cantos-Barreda1, Damián Escribano2, Adriana Egui3, Manuel C López3, José J Cerón1, Luis J Bernal1, Silvia Martínez-Subiela1.   

Abstract

In this study, the circadian rhythm of IgG2 and IgA specific antibodies in serum and saliva samples of 6 dogs experimentally infected with Leishmania infantum was assessed. Sampling was performed at 8.00, 12.00, 16.00, 20.00, and 00.00 h on two consecutive days. Anti-Leishmania antibody levels in serum were expressed without any correction, whereas in saliva were shown in different ways: without any correction, adjusted by protein concentration and corrected by the salivary flow rate. No significant differences in anti-Leishmania IgG2 antibody levels in serum and saliva samples with or without correction were found. Significant differences were found when anti-Leishmania IgA levels were corrected by the salivary flow rate. In addition, a greater intra-individual variation of antibody levels was observed in saliva than in serum. However, this variation did not modify the serological status of the dogs. Therefore, it could be concluded that there is no circadian rhythm in serum and saliva samples and sampling can be performed at any time of the day.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-Leishmania antibodies; Circadian rhythm; Dog; Saliva; Serum; TR-IFMA

Mesh:

Substances:

Year:  2019        PMID: 31760362     DOI: 10.1016/j.cimid.2019.101389

Source DB:  PubMed          Journal:  Comp Immunol Microbiol Infect Dis        ISSN: 0147-9571            Impact factor:   2.268


  1 in total

1.  Detection of specific antibodies against Leishmania infantum in canine serum and oral transudate using an in-house ELISA.

Authors:  Marta Baxarias; Júlia Viñals; Alejandra Álvarez-Fernández; Mª Magdalena Alcover; Laia Solano-Gallego
Journal:  Parasit Vectors       Date:  2022-05-10       Impact factor: 4.047

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.